Medtronic launches new guidewire to support TAVR procedures
October 25, 2025
Medtronic (NYSE: MDT)+
today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.
Medtronic (NYSE: MDT)+
today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.
Blood tests are among the most common tools in medicine. Scientists are working to make blood cell imaging faster and more intuitive so that doctors can make fast and accurate diagnostic decisions.
BEAVERTON, Ore., Oct. 24, 2025 /PRNewswire/ — YorLabs, Inc., a medical technology company pioneering next-generation intracardiac imaging solutions for electrophysiology (EP) and interventional cardiology (IC) procedures, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s YorLabs Intracardiac Imaging System – a first-of-its-kind, zero-capex ultrasound platform designed to simplify workflow, reduce cost, and enhance procedural efficiency inside the cath lab.
The tool integrates with the current laboratory infrastructure, captures images of embryos and creates an AI score.
The device has shown to be advantageous for individuals with neurological or orthopaedic disorders.
The expanded FDA clearance makes NeurAxis’ IB-Stim the first FDA approval for a treatment that specifically addresses functional dyspepsia.
Novel technology delivers enhanced image contrast and resolution for confident decisions
An endoscopy—using a fiber‐optic tube to peer inside the body and collect biopsy samples—can be an invaluable way to detect cancer of the esophagus. But sometimes, an endoscopy can miss esophageal cancer, which doesn’t get detected until weeks or months later.
Researchers have created a new type of drug molecule that can precisely destroy TERRA, an RNA molecule that helps certain cancer cells survive. Using advanced “RIBOTAC” technology, their compound finds TERRA inside cells and breaks it down without harming healthy molecules. This discovery could pave the way for a new generation of RNA-based cancer treatments, targeting the disease at its genetic roots rather than just its symptoms.
Randomized, controlled clinical trials are crucial for telling whether a new treatment is safe and effective. But often scientists don’t fully report the details of their trials in a way that allows other researchers to gauge how well they designed and conducted those studies.